TrialsgrambetaRCTs are beautiful

EVOLVE

2012

Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events

In 3,883 haemodialysis patients with secondary hyperparathyroidism, cinacalcet did not significantly reduce death or cardiovascular events compared with placebo.

Result

Efficacy: Composite of death or first non-fatal cardiovascular eventHR 0.93 (95% CI 0.85-1.02) · P = 0.11

Below 1 favours cinacalcet, above 1 favours placebo.

Event rates
Absolute difference
1.0 points

The absolute difference is derived from the event rates.

Also reported: Age-adjusted HR 0.88.

Original publication
Subtopic
Mineral & bone disorder
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Chertow GM, et al. N Engl J Med. 2012;367(26):2482-2494.doi 10.1056/NEJMoa1205624

Discussion & critique

No universal CV benefit; high dropout and crossover; cinacalcet is now used selectively in refractory disease.

Discussed in podcasts